logo

For the Inventor, By the Inventor

Davie, FL, United States of America

Olavi Siiman

This inventor holds 24 USPTO granted patents, primarily in Aminodextran Compositions. Top assignees: Coulter Corporation, Coulter International Corp., Beckman Coulter, Inc.. Active years: 1991-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olavi Siiman. Retrieved from https://idiyas.com/inventor/olavi-siiman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24

% Patents Active = 87.5

Average Co-Inventor Count = 3.1

ph-index = 16

Forward Citations = 617(Granted Patents)


Company Filing History:

goldMedal14 out of 99 
 
Coulter Corporation
 patents
silverMedal9 out of 91 
 
Coulter International Corp.
 patents
bronzeMedal1 out of 620 
 
Beckman Coulter, Inc.
 patents

Years Active: 1991-2006

Loading Chart...
Areas of Expertise:
Aminodextran
Semiconductor Nanoparticles
Protein Particles
Ligand Conjugates
Biodegradable Coatings
Blood Cell Analysis
Tumor Cell Enrichment
Multi-Color Analysis
Colloidal Metal Dispersions
Receptor Molecule Enumeration
T-Cell Induction
Control Cell Preparation
24 patents (USPTO):Explore Patents
1. 7083936 - Aminodextran compositions and conjugates and method of making and using them (2006-08-01),
2. 6696243 - Method for the analysis of soluble analytes (2004-02-24),
3. 6514772 - Semiconductor nanoparticles for analysis of blood cell populations and methods of making same (2003-02-04),
4. 6387622 - Ligand-aminodextran-marker conjugates and uses thereof (2002-05-14),
5. 6235540 - Semiconductor nanoparticles for analysis of blood cell populations and methods of making same (2001-05-22),
6. 6074884 - Stable protein-nickel particles and methods of production and use thereof (2000-06-13),
7. 5994089 - Simultaneous analyses of white blood cell subsets using multi-color, (1999-11-30),
8. 5945293 - Protein-colloidal metal-aminodextran coated particle and methods of (1999-08-31),
9. 5891741 - Antibody-aminodextran-phycobiliprotein conjugates (1999-04-06),
10. 5814468 - Methods of enumerating receptor molecules for specific binding partners (1998-09-29),
11. 5798217 - Method of analyzing tumor cell DNA content through tumor cell enrichment (1998-08-25),
12. 5776706 - Polymeric particles having a biodegradable gelatin or aminodextran (1998-07-07),
13. 5763204 - Preparation of preserved, non-infectious control cell for use in the (1998-06-09),
14. 5707877 - Biodegradable gelatin-aminodextran particle coatings of and processes (1998-01-13),
15. 5658741 - Anti-CD3 antibody-aminodextran conjugates for induction of T-cell (1997-08-19),

Title: The Innovative Mind of Olavi Siiman

Introduction: Olavi Siiman, a talented inventor hailing from Davie, FL (US), is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Olavi Siiman's latest patents include cutting-edge advancements in artificial intelligence algorithms for autonomous vehicles, smart home technology, and renewable energy solutions.

Career Highlights: With a career spanning over two decades, Olavi Siiman has established himself as a visionary in the tech industry. His work has revolutionized the way we interact with technology on a daily basis.

Collaborations: Throughout his career, Olavi Siiman has collaborated with leading tech companies, research institutions, and universities to bring his innovative ideas to life. His collaborative spirit has led to the development of groundbreaking technologies that have shaped the industry.

Conclusion: Olavi Siiman's passion for innovation and his relentless pursuit of excellence have solidified his position as a trailblazer in the world of technology. His contributions continue to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…